金贝痰咳清颗粒联合孟鲁司特钠治疗儿童喘息性支气管炎的临床研究
|
摘要
目的研究金贝痰咳清颗粒联合孟鲁司特钠咀嚼片治疗儿童喘息性支气管炎的临床疗效。方法选取2016年6月—2018年6月乐东黎族自治县人民医院治疗的80例喘息性支气管炎患儿作为研究对象,采用计算机单盲随机分组法将患者分为对照组和治疗组,每组各40例。对照组患儿口服孟鲁司特钠咀嚼片,4mg/次,1次/d;治疗组患儿在对照组治疗的基础上口服金贝痰咳清颗粒,7g/次,3次/d。两组患儿均连续治疗14d。观察两组患者的临床疗效,同时比较两组的临床症状缓解时间、门诊治疗时间、肺功能指标和炎症因子水平。结果治疗后,对照组和治疗组的总有效率分别为75.00%、92.50%,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组喘息缓解时间、哮鸣音消失时间、咳嗽缓解时间和门诊治疗时间均显著短于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组峰值呼气流速(PEF)、第1秒用力呼气容积(FEV1)和FEV1/FVC水平均显著升高,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后治疗组肺功能指标显著高于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)、白三烯E4(LTE4)和嗜酸性细胞阳离子蛋白(ECP)水平均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗后治疗组炎症因子水平显著低于对照组,两组比较差异具有统计学意义(P<0.05)。结果金贝痰咳清颗粒联合孟鲁司特钠咀嚼片可有效改善喘息性支气管炎患儿的临床症状,提高疗效,改善肺功能和炎症状态,且不良反应小,具有一定临床推广应用价值。
Objective To study the efficacy of Jinbei Tankeqing Granules combined with Montelukast Sodium Chewable Tablets in treatment of asthmatic bronchitis in children. Methods Children(80 cases) with asthmatic bronchitis in People's Hospital of Ledong Li Nationality Autonomous County from June 2016 to June 2018 were randomly divided into control and treatment groups according to computer single blind method, and each group had 40 cases. Children in the control group were po administered with Montelukast Sodium Chewable Tablets, 4 mg/time, once daily. Children in the treatment group were po administered with Jinbei Tankeqing Granules on the basis of the control group, 7 g/time, three times daily. Children in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the clinical symptom remission time, outpatient treatment time, lung function indexes, and the levels of serum inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 75.00% and 92.50%, respectively, and there was difference between two groups(P < 0.05). After treatment,asthma remission time, wheezing disappearance time, cough remission time, and outpatient treatment time in the treatment group were significantly shorter than those in the control group, and there was difference between two groups(P < 0.05). After treatment, the levels of PEF, FEV1, and FEV1/FVC in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the lung function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of IL-6, IL-8, TNF-α, LTE4, and ECP in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the levels of serum inflammatory factors in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Jinbei Tankeqing Granules combined with Montelukast Sodium Chewable Tablets can effectively improve the clinical symptoms of asthmatic bronchitis in children, increase the curative effect, and improve lung function and inflammatory state with low adverse reactions, which has a certain clinical application value.
Objective To study the efficacy of Jinbei Tankeqing Granules combined with Montelukast Sodium Chewable Tablets in treatment of asthmatic bronchitis in children. Methods Children(80 cases) with asthmatic bronchitis in People's Hospital of Ledong Li Nationality Autonomous County from June 2016 to June 2018 were randomly divided into control and treatment groups according to computer single blind method, and each group had 40 cases. Children in the control group were po administered with Montelukast Sodium Chewable Tablets, 4 mg/time, once daily. Children in the treatment group were po administered with Jinbei Tankeqing Granules on the basis of the control group, 7 g/time, three times daily. Children in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the clinical symptom remission time, outpatient treatment time, lung function indexes, and the levels of serum inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 75.00% and 92.50%, respectively, and there was difference between two groups(P < 0.05). After treatment,asthma remission time, wheezing disappearance time, cough remission time, and outpatient treatment time in the treatment group were significantly shorter than those in the control group, and there was difference between two groups(P < 0.05). After treatment, the levels of PEF, FEV1, and FEV1/FVC in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the lung function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of IL-6, IL-8, TNF-α, LTE4, and ECP in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the levels of serum inflammatory factors in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Jinbei Tankeqing Granules combined with Montelukast Sodium Chewable Tablets can effectively improve the clinical symptoms of asthmatic bronchitis in children, increase the curative effect, and improve lung function and inflammatory state with low adverse reactions, which has a certain clinical application value.
引文
[1]张喜英,赵文利,何念海.喘息性支气管炎与儿童哮喘相关性的初步探讨[J].重庆医学,2008,37(9):918-919.
[2]崔如众,何权瀛,丁东杰.近几年关于慢性喘息型支气管炎研究进展[J].中华结核和呼吸杂志,2000,23(3):186-187.
[3]杨洁,李静,周耀铃.孟鲁司特钠治疗小儿哮喘临床研究[J].实用药物与临床,2016,19(5):606-609.
[4]张丽君.金贝痰咳清颗粒治疗慢性喘息性支气管炎疗效观察[J].实用心脑肺血管病杂志,2012,20(3):458-459.
[5]胡亚美,江载芳,申昆玲,等.诸福堂实用儿科学[M].第8版.北京:人民卫生出版社,2015:1199-1201.
[6]陈永红.儿科疾病诊断与疗效标准[M].上海:上海中医药大学出版社,2006:53.
[7]姚海棠.喘息型支气管炎治疗研究进展[J].中国医药指南,2012,10(3):53-55.
[8]赵玉歧,孙宝华.小儿喘息性疾病的诊断与治疗进展[J].新医学,2006,37(8):543-545.
[9]龙秀兰.孟鲁司特联合布地奈德福莫特罗治疗慢性喘息性支气管炎的临床观察[J].现代临床医学,2012,38(1):22-23.
[10]申玉,韩雄信,李若飞.孟鲁司特钠咀嚼片联合多索茶碱治疗喘息性支气管炎68例[J].中国药业,2015,24(5):60-62.
[11]王斌,吴静华,李永权.孟鲁司特钠治疗小儿喘息性支气管炎的疗效及对气道高反应性的预防效果分析[J].医学综述,2016,22(8):1600-1602.
[12]张丽君.金贝痰咳清颗粒治疗慢性喘息性支气管炎疗效观察[J].实用心脑肺血管病杂志,2012,20(3):458-459.
[13]陈尚君,费秀斌,蔡栋梁.金贝痰咳清治疗老年慢性支气管炎急性发作疗效观察[J].实用心脑肺血管病杂志,2012,20(1):138-139.
[14]管丽华,李建高,樊必夫,等.慢性支气管炎患者血清CG、IL-2、IL-8和TNF-α变化的探讨[J].放射免疫学杂志,2009,22(4):347-348.
[15]路明,郭爱华,武怡,等.婴幼儿喘息性支气管炎患者血清ECP和IgE改变及意义[J].徐州医学院学报,2003,23(5):439-440.
[16]侯秀玲,王敬敏,刘冬梅,等.LTE4和鼻咽分泌物ECP对毛细支气管炎治疗和预后的影响[J].检验医学与临床,2015,12(24):3637-3638.
[17]阮学东,陈啸洪,董传昌,等.毛细支气管炎患儿血IL-4、IL-5、IL-6、T-IgE变化及治疗对策[J].临床儿科杂志,2003,21(12):787-789.
[2]崔如众,何权瀛,丁东杰.近几年关于慢性喘息型支气管炎研究进展[J].中华结核和呼吸杂志,2000,23(3):186-187.
[3]杨洁,李静,周耀铃.孟鲁司特钠治疗小儿哮喘临床研究[J].实用药物与临床,2016,19(5):606-609.
[4]张丽君.金贝痰咳清颗粒治疗慢性喘息性支气管炎疗效观察[J].实用心脑肺血管病杂志,2012,20(3):458-459.
[5]胡亚美,江载芳,申昆玲,等.诸福堂实用儿科学[M].第8版.北京:人民卫生出版社,2015:1199-1201.
[6]陈永红.儿科疾病诊断与疗效标准[M].上海:上海中医药大学出版社,2006:53.
[7]姚海棠.喘息型支气管炎治疗研究进展[J].中国医药指南,2012,10(3):53-55.
[8]赵玉歧,孙宝华.小儿喘息性疾病的诊断与治疗进展[J].新医学,2006,37(8):543-545.
[9]龙秀兰.孟鲁司特联合布地奈德福莫特罗治疗慢性喘息性支气管炎的临床观察[J].现代临床医学,2012,38(1):22-23.
[10]申玉,韩雄信,李若飞.孟鲁司特钠咀嚼片联合多索茶碱治疗喘息性支气管炎68例[J].中国药业,2015,24(5):60-62.
[11]王斌,吴静华,李永权.孟鲁司特钠治疗小儿喘息性支气管炎的疗效及对气道高反应性的预防效果分析[J].医学综述,2016,22(8):1600-1602.
[12]张丽君.金贝痰咳清颗粒治疗慢性喘息性支气管炎疗效观察[J].实用心脑肺血管病杂志,2012,20(3):458-459.
[13]陈尚君,费秀斌,蔡栋梁.金贝痰咳清治疗老年慢性支气管炎急性发作疗效观察[J].实用心脑肺血管病杂志,2012,20(1):138-139.
[14]管丽华,李建高,樊必夫,等.慢性支气管炎患者血清CG、IL-2、IL-8和TNF-α变化的探讨[J].放射免疫学杂志,2009,22(4):347-348.
[15]路明,郭爱华,武怡,等.婴幼儿喘息性支气管炎患者血清ECP和IgE改变及意义[J].徐州医学院学报,2003,23(5):439-440.
[16]侯秀玲,王敬敏,刘冬梅,等.LTE4和鼻咽分泌物ECP对毛细支气管炎治疗和预后的影响[J].检验医学与临床,2015,12(24):3637-3638.
[17]阮学东,陈啸洪,董传昌,等.毛细支气管炎患儿血IL-4、IL-5、IL-6、T-IgE变化及治疗对策[J].临床儿科杂志,2003,21(12):787-789.